-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our 12-month price target to $189 from $193. This new target is 16.7x our 2026 EPS estimate, above ALGN's one-year historical forward average of 15.7x but well below its three- and five-year averages of 24.3x and 31.4x, respectively. We raise our 2026 EPS estimate by $0.06 to $11.34 and our 2027 estimate by $0.15 to $12.36. While interest rates are expected to continue declining, we think North American patient volumes remain challenged in the current macro environment, with inflationary pressures weighing on consumer sentiment and elective medical spending. Average per case shipment price rose around 1% to $1,250 during Q1, up $10 sequentially and Y/Y, though ALGN guides for a 1%-2% decline in pricing during 2026.